ACS Infectious Diseases

ACS Infectious Diseases is a monthly peer-reviewed journal published by the American Chemical Society since 2015 that highlights the role of chemistry in infectious disease research, and its 2025 Journal Impact Factor is 4.5《ACS 传染病学》（ACS Infectious Diseases）是美国化学会（American Chemical Society）自 2015 年出版的月刊同行评审期刊，聚焦化学在传染病研究中的作用，2025 年期刊影响因子为 4.5。

Scope

• The journal is the first to highlight chemistry and its role in the multidisciplinary and collaborative field of infectious disease research, and it aims to bridge the gap between chemistry and the biology of infectious diseases该刊是首个凸显化学在传染病这一多学科协作研究中作用的期刊，致力于在化学与传染病生物学之间架起桥梁。
• The scope encompasses all aspects of chemistry relating to infectious disease research, including research on pathogens, host-pathogen interactions, therapeutics, diagnostics, vaccines and drug-delivery systems其范围涵盖与传染病研究相关的化学各个层面，包括病原体、宿主与病原体相互作用、治疗、诊断、疫苗与药物递送系统的研究。
• Submissions covering all pathogens are encouraged, including bacteria, viruses, parasites and fungi, as well as microbial toxins and prions该刊鼓励涵盖所有病原体的投稿，包括细菌、病毒、寄生虫与真菌，以及微生物毒素与朊病毒。
• Recurring topics include therapeutics, diagnostics, anti-infective biomaterials and drug delivery systems, drug resistance, pathogens and host-pathogen interactions, and vaccines常规主题包括治疗、诊断、抗感染生物材料与药物递送系统、耐药性、病原体与宿主相互作用以及疫苗。
• The journal has broadened its scope to welcome chemistry-driven immunomodulatory therapeutics, host-directed antimicrobial therapeutics, biomaterials that mitigate infections, and studies of host-microbiome and pathogen interactions该刊已拓宽范围，欢迎化学驱动的免疫调节疗法、靶向宿主的抗微生物疗法、可减轻感染的生物材料，以及宿主微生物组与病原体相互作用的研究。
• Accepted manuscript types are Articles, Letters, Perspectives, Reviews and Viewpoints可接受的稿件类型包括研究论文、快报、观点、综述与评论。

History

• The journal was launched in 2015 by the American Chemical Society as the first journal to highlight the role of chemistry in infectious disease research, marking a new direction for the Society该刊于 2015 年由美国化学会创办，是首个凸显化学在传染病研究中作用的期刊，标志着该学会的一个新方向。
• It was created to address the surge in infectious disease-related research, and its inaugural Editor-in-Chief was Courtney Aldrich, a chemist working on tuberculosis其创办旨在应对传染病相关研究的激增，首任主编为从事结核病研究的化学家（Courtney Aldrich）。
• Over its first decade the journal grew into an umbrella title receiving content on therapeutics, diagnostics, vaccines, drug resistance, host-pathogen interactions, anti-infective biomaterials and drug delivery在最初的十年里，该刊发展为一份综合性刊物，接收治疗、诊断、疫苗、耐药性、宿主与病原体相互作用、抗感染生物材料与药物递送等方面的内容。
• With the December 2024 issue the journal completed ten years of publication, and by 2026 it had reached its twelfth volume随着 2024 年 12 月一期的出版，该刊完成了十年出版历程，至 2026 年已出版至第 12 卷。
• It appears monthly, publishing twelve issues a year, and it is a hybrid journal that offers an open access option alongside subscription publication该刊为月刊，每年出版 12 期，属混合期刊，在订阅出版之外还提供开放获取选项。
• Its 2025 Journal Impact Factor is 4.5, following 3.8 in 2024 and 5.578 in 2022, and it is ranked in the first quartile of infectious diseases该刊 2025 年影响因子为 4.5，2024 年为 3.8，2022 年为 5.578，位列传染病学一区。
• The journal is indexed in the Science Citation Index Expanded, Scopus and PubMed该刊被科学引文索引扩展版、Scopus 与 PubMed 收录。

Editors

• The Editor-in-Chief is Jayanta Haldar of the New Chemistry Unit and School of Advanced Materials at the Jawaharlal Nehru Centre for Advanced Scientific Research in Bangalore, India主编为（Jayanta Haldar），任职于印度班加罗尔贾瓦哈拉尔·尼赫鲁高级科学研究中心新化学研究室与先进材料学院。
• The journal's editors are active researchers versed in both chemistry and the biology of infectious diseases该刊编辑均为在化学与传染病生物学两方面均有造诣的活跃研究者。
• The founding Editor-in-Chief, Courtney Aldrich, led the journal at its 2015 launch创刊主编（Courtney Aldrich）在 2015 年创刊时领导该刊。
• Manuscripts are handled by associate editors and an editorial advisory board, and they are peer reviewed before publication稿件由副主编与编辑顾问委员会处理，并在发表前实行同行评审。
• The journal established an Early Career Award in 2016, originally known as the Young Investigator Award and presented jointly with an American Chemical Society division该刊于 2016 年设立早期职业奖，原名青年研究者奖，与美国化学会某分会联合颁发。